North Star Fibroid Clinic Opens, Offering Women a Non-Surgical Solution for Uterine Fibroids
Endovascular Doctors Offer Non-Surgical Treatment to Remove Uterine Fibroids Without Surgery Using Popular UFE Procedure.
'We are excited to offer UFE as a safe and effective solution for women suffering from uterine fibroids,' — Amin Astani, M.D.
MINNEAPOLIS, MN, UNITED STATES, February 11, 2025 / EINPresswire.com / -- North Star Vascular and Interventional proudly announces the opening of the North Star Fibroid Clinic in Minneapolis, dedicated to providing women with an effective, non-surgical treatment for uterine fibroids.
The clinic specializes in Uterine Fibroid Embolization (UFE)—an FDA-approved, minimally invasive procedure that treats fibroids without surgery, incisions, or a lengthy recovery period.
Uterine fibroids affect millions of women, often causing heavy menstrual bleeding, bloating, pelvic pain, frequent urination, and discomfort during intercourse. While traditional treatments like hysterectomy and myomectomy remain common, these surgeries come with significant risks, high costs, and long recovery times.
UFE offers a safe, highly effective alternative. The board-certified, fellowship-trained Vascular and Interventional Radiologists at North Star Fibroid Clinic use advanced X-ray imaging to guide a thin catheter through the wrist or groin to the arteries supplying the fibroids. Tiny particles are then injected into these blood vessels, cutting off oxygenated blood flow to the fibroids. This causes the fibroids to shrink and disappear, leading to symptom relief.
Why Choose UFE?
✅ 93% of women report symptom improvement within days
✅ Minimally invasive – no incisions, no general anesthesia
✅ Outpatient procedure – typically under one hour, with same-day discharge
✅ Faster recovery – most patients return to daily activities within a few days
✅ Preserves the uterus – unlike hysterectomy, UFE allows women to keep their uterus
'We are excited to offer UFE as a safe and effective solution for women suffering from uterine fibroids,' said Dr. Amin Astani, Medical Director at North Star Fibroid Clinic. 'This procedure allows us to treat fibroid-related symptoms without invasive surgery or hospital stays, helping women recover quickly and regain their quality of life.'
About North Star Fibroid Clinic
North Star Fibroid Clinic is a premier healthcare provider in Minneapolis, specializing in minimally invasive, non-surgical fibroid treatment. With a commitment to innovation, patient-centered care, and advanced technology, the clinic provides personalized treatment plans in a compassionate, supportive environment.
For more information, visit northstarfibroidclinic.com or call 952-522-4885.
Ali Yassine
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold
SCYNEXIS, Inc. (NASDAQ:SCYX) has officially restarted patient dosing in its Phase III MARIO trial for Brexafemme (ibrexafungerp) after the FDA lifted a nearly two-year clinical hold. The hold, initiated over concerns of beta-lactam contamination at the original manufacturing facility, was removed once new drug batches were produced at a separate location. With trial sites now reactivated, patient enrollment has resumed, reaching about 25% of its 220-participant goal. A pharmacist technician sorting pills in a drug pharmacy. The MARIO trial explores Brexafemme's use as an oral follow-up treatment to IV echinocandins for invasive candidiasis, a life-threatening fungal infection. SCYNEXIS, Inc. (NASDAQ:SCYX) received a $10 million milestone payment from GSK after the first new patient was dosed, though disagreements over further payments and trial duties have sparked tension between the two partners. Previously recalled in 2023 due to contamination risks, Brexafemme had FDA approval for treating VVC. While its commercial progress has faced setbacks, projected global revenue could reach $139 million by 2031 if development succeeds. While we acknowledge the potential of SCYX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SCYX and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) on Friday announced results from two Phase 3 trials of itepekimab in chronic obstructive pulmonary disease (COPD) patients. Phase 3 AERIFY-1 trial evaluating itepekimab in adults who were former smokers with inadequately controlled COPD met the primary endpoint of significantly reducing moderate or severe acute exacerbations by 27% compared to placebo at week 52, a clinically meaningful benefit. A second Phase 3 trial, AERIFY-2, did not meet the same primary endpoint. Despite showing some benefit earlier in the trial (at week 24), itepekimab did not achieve a statistically significant reduction in moderate or severe exacerbations at week 52 in the second the trials, patients were randomized to receive itepekimab every two weeks (AERIFY-1: n=375; AERIFY-2: n=326), every four weeks (AERIFY-1: n=377; AERIFY-2: n=303), or placebo (AERIFY-1: n=375; AERIFY-2: n=324), which was added to inhaled triple or double standard-of-care therapy. The primary endpoint for AERIFY-1 and AERIFY-2 was the reduction in the annualized rate of acute moderate or severe COPD exacerbations with itepekimab treatment. The total number of exacerbations was lower than prospectively anticipated, decreasing the power of both trials. Enrollment largely occurred during the global COVID-19 pandemic, which could have contributed to the lower overall exacerbation rates. The safety profile of itepekimab was consistent across dosing regimens, and adverse events (AEs) were generally comparable between treatment and placebo groups. Regeneron and Sanofi will review the data and discuss it with regulatory authorities to evaluate the next steps. Itepekimab is also being evaluated in other respiratory conditions, including chronic rhinosinusitis without nasal polyps, chronic rhinosinusitis with nasal polyps, and non-cystic fibrosis bronchiectasis. In November 2024, Regeneron and Sanofi's Dupixent gained FDA approval for COPD, marking its sixth U.S. indication since its first use for atopic dermatitis seven years ago. This expansion positions Dupixent as the first targeted therapy for COPD, a significant leap in treating this progressive lung condition that impedes breathing due to obstructed airflow. Last Thursday, the U.S. Food and Drug Administration (FDA) approved GSK Plc's (NYSE:GSK) Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled COPD and an eosinophilic phenotype. Last June, the FDA approved Verona Pharma plc's (NASDAQ:VRNA) Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years. In May, Sanofi announced it will invest at least $20 billion in the U.S. through 2030. Research and development, plus U.S. manufacturing, will receive the bulk of the spending. The company also expects higher job creation within the communities where Sanofi and its partners are located, which will help enhance the U.S. supply chain. Earlier in May, Regeneron secured the winning bid in the bankruptcy auction for key assets of 23andMe Holding Co. in a $256 million deal to boost its genetics-based drug discovery efforts. Price Action: REGN stock is down 9.98% at $545, and SNY stock is down 4.57% at $49.96 during the premarket session at last check Friday. Read Next:Photo by Marianne Campolongo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? REGENERON PHARMACEUTICALS (REGN): Free Stock Analysis Report SANOFI (SNY): Free Stock Analysis Report This article Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2025 MedTech Innovation Spotlight
MINNEAPOLIS, May 30, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will participate in the Wells Fargo 2025 MedTech Innovation Spotlight on Friday, June 13, 2025. Inspire is scheduled to present at 12:00 p.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire's Investor website at About Inspire Medical SystemsInspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit Investor and Media ContactEzgi YagciVice President, Investor Relationsezgiyagci@ in to access your portfolio
